Dr. Reddy’s Laboratories (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active pharmaceutical ingredients (API) business and custom pharmaceutical services (CPS) business, and Proprietary Products segment, which consists of DRL’s new chemical entities (NCEs) business, its Differentiated Formulations business and its dermatology focused specialty business operated through Promius Pharma. On March 27, 2012, DRL launched quetiapine fumarate tablets. On March 2, 2012, it launched ziprasidone hydrochloride capsules. On October 24, 2011, DRL launched olanzapine tablets. On July 25, 2011, it launched fondaparinux sodium injection.
HQHyderabad, IN
Size (employees)22,681 (est)
Dr. Reddy's Laboratories was founded in 1984 and is headquartered in Hyderabad, IN
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Dr. Reddy's Laboratories Office Locations

Dr. Reddy's Laboratories has an office in Hyderabad
Show all (1)
Report incorrect company information

Dr. Reddy's Laboratories Online and Social Media Presence

Embed Graph
Report incorrect company information

Dr. Reddy's Laboratories News and Updates

Buy Amara Raja Batteries, Dr. Reddy's Laboratories, says Religare Broking

Top trading ideas by Religare Broking
Report incorrect company information

Dr. Reddy's Laboratories Company Life and Culture

Report incorrect company information